The FDA has expanded the approval of Odactra to include treatment of house dust mite-induced allergic rhinitis in pediatric patients aged 5 to 11 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback